Key result
Valve-in-valve-in-valve TAVR achieves ~78% technical success with no 30-day mortality.
Why the study?
Many younger and lower-risk TAVR patients will outlive their first two bioprosthetic valves and require a third aortic valve intervention. However, evidence on this valve-in-valve-in-valve (ViViV) approach is scattered across case reports, and patient-level outcomes had not been synthesized.
Does valve-in-valve-in-valve transcatheter aortic valve replacement achieve technical and device success in patients requiring a third aortic valve intervention?
Systematic Review (n=32)
Does valve-in-valve-in-valve transcatheter aortic valve replacement achieve technical and device success in patients requiring a third aortic valve intervention?
Answers are grounded in this paper and cite their sources.
Valve-in-valve-in-valve TAVR is a feasible option for a failing second bioprosthesis with high technical success in staged procedures, though hemodynamic outcomes are limited by residual gradients in small surgical valves.
Transcatheter aortic valve replacement (TAVR) is increasingly offered to younger and lower-risk patients, many of whom will outlive both their first and second bioprosthetic valves and need a third aortic valve intervention. Evidence on this valve-in-valve-in-valve (ViViV) approach is scattered across case reports, and patient-level outcomes have not been synthesized. We performed a systematic review, reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement, of MEDLINE, Embase, Scopus, and Google Scholar, supplemented by web and citation searching, for case reports and case series describing a third aortic valve intervention in which the second and third procedures were transcatheter. Outcomes were adjudicated using the Valve Academic Research Consortium 3 (VARC-3) definitions, and risk of bias was assessed with the Joanna Briggs Institute (JBI) checklist for case reports and the Risk of Bias in Systematic Reviews (ROBIS) tool. Thirty-one reports describing 32 patients (median age 76 years) were included, and 26 patients had a surgical first valve. The third valve was implanted in a staged procedure in 24 patients, a median of 3.8 years after the second, and as a bail-out during or within hours of the second procedure in eight. A self-expanding valve followed by a balloon-expandable valve was the most common combination. VARC-3 technical success was achieved in 25 of 32 patients, and all seven failures were bail-outs that required more than one valve in the same procedure. The median post-procedure mean gradient was 12 mmHg, but five of 23 patients with reported values had a gradient of at least 20 mmHg, all after a 23-mm surgical bioprosthesis or a homograft, and 30-day device success was achieved in 11 of 24 evaluable patients. No deaths within 30 days were reported, and coronary obstruction occurred once. ViViV TAVR is a feasible option when a second bioprosthesis fails, but residual gradients in small surgical valves limit its hemodynamic results, publication bias likely inflates reported success, and prospective registries are needed.
No takes yet. Share an insight, caveat, or question.
Singla et al. (2026) conducted a systematic review in Failed second bioprosthetic aortic valve requiring a third aortic valve intervention (n=32). Valve-in-valve-in-valve (ViViV) transcatheter aortic valve replacement (TAVR) was evaluated on VARC-3 technical success. Valve-in-valve-in-valve TAVR achieved VARC-3 technical success in 78.1% (25/32) of patients and 30-day device success in 45.8% (11/24), with no 30-day mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: